1-5 of 5
Maria B.L. Leijs
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma: Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial

Marie José Kersten, Martin Dreyling, Kim M. Linton, Dana Chitu, Sanne Tonino, Marcel Kap, Roberto D Liu, Martine E.D. Chamuleau, Hein P.J. Visser, Eva De Jongh, Erik WAF Marijt, Maria B.L. Leijs, Yavuz M. Bilgin, Jan Dürig, Pamela McKay, Tjeerd J.F. Snijders, Andrew Pettitt, Monique C. Minnema, Gabriele Prange-Krex, Maria Cuijpers, Lara H. Böhmer, Lidwine W. Tick, Axel Florschütz, Matthijs Silbermann, Rob Fijnheer, Aart Beeker, Nelleke Tolboom, Cristina Mitea, Anne IJ Arens, Gerben JC Zwezerijnen, Wolfram Klapper, Sarah E. Coupland, Daphne de Jong, Jeanette K. Doorduijn, Josée M. Zijlstra
Journal: Blood
Blood (2022) 140 (Supplement 1): 2283–2285.
https://doi.org/10.1182/blood-2022-156085
Published: 2022
Journal Articles

Ixazomib, Daratumumab and Low Dose Dexamethasone in Intermediate-Fit Patients with Newly Diagnosed Multiple Myeloma (NDMM); Results of Induction Treatment of the Phase II HOVON 143 Study

Kaz Groen, Claudia A.M. Stege, Kazem Nasserinejad, Koen de Heer, Roel J.W. Van Kampen, Maria B.L. Leijs, Noortje Thielen, Matthijs Westerman, Ka Lung Wu, Inge Ludwig, Djamila Issa, Gerjo A. Velders, Marie-Christiane Vekemans, Niels W.C.J. van de Donk, Gert-Jan Timmers, Pieter Sonneveld, Maarten R. Seefat, Fransien Croon-de Boer, Lidwine W. Tick, Ellen van der Spek, Esther G.M. De Waal, Maaike Sohne, Paula F Ypma, Inger S. Nijhof, Saskia K. Klein, Mark-David Levin, Sonja Zweegman
Journal: Blood
Blood (2021) 138 (Supplement 1): 80.
https://doi.org/10.1182/blood-2021-152112
Published: 2021
Journal Articles

A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial

Barbara Eichhorst, Carsten Niemann, Arnon P. Kater, Moritz Fürstenau, Julia Von Tresckow, Can Zhang, Sandra Robrecht, Michael Gregor, Gunnar Juliusson, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Vesa Lindström, Caspar Da Cunha-Bang, Christof Schneider, Christian Bjørn Poulsen, Thomas Illmer, Björn Schöttker, Ann Janssens, Ilse Christiansen, Thomas Noesslinger, Michael Baumann, Marjolein van der Klift, Ulrich Jaeger, Henrik Frederiksen, Maria B.L. Leijs, Mels Hoogendoorn, Kourosh Lotfi, Holger Hebart, Tobias Gaska, Harry R. Koene, Florian Simon, Nisha De Silva, Anna-Maria Fink, Kirsten Fischer, Clemens-Martin Wendtner, Karl-Anton Kreuzer, Matthias Ritgen, Monika Brüggemann, Eugen Tausch, Mark-David Levin, Marinus H.J. Van Oers, Christian H. Geisler, Stephan Stilgenbauer, Michael Hallek
Journal: Blood
Blood (2021) 138 (Supplement 1): 71.
https://doi.org/10.1182/blood-2021-146161
Published: 2021
Journal Articles

Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (Ixa Dara dex) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; Results of the Interim Efficacy Analysis of the Phase II HOVON 143 Study

Claudia A.M. Stege, MD, Kazem Nasserinejad, Ellen van der Spek, MD PhD, Roel J.W. Van Kampen, MD PhD, Maaike Sohne, MD, Noortje Thielen, MD PhD, Yavuz Bilgin, MD PhD, Esther G.M. De Waal, MD, Inge Ludwig, MD MSc, Maria B.L. Leijs, MD, Alain Kentos, MD, Gert Jan Timmers, MD PhD, Koen de Heer, MD, Matthijs Westerman, MD, Marie Christiane Vekemans, Nazik Durdu-Rayman, MD, Nicole C.H.P. van der Burg-de Graauw, MD, Niels W. C. J. Van De Donk, MD PhD, Pieter Sonneveld, Saskia K. Klein, MD PhD, Mark-David Levin, MD PhD, Sonja Zweegman, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 695.
https://doi.org/10.1182/blood-2019-121694
Published: 2019
Journal Articles

Ixazomib-Thalidomide-Low Dose Dexamethasone (ITd) Induction Followed By Maintenance Therapy with Ixazomib or Placebo in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem Cell Transplantation; Results from the Randomized Phase II HOVON-126/Nmsg 21#13 Trial

Sonja Zweegman, MDPhD, Fredrik H. Schjesvold, MDPhD, Bronno van der Holt, PhD, Mark-David Levin, MDPhD, Claudia A.M. Stege, MD, Anders Waage, MD PhD, Maria B.L. Leijs, MD, Saskia K. Klein, MDPhD, Damian L. Szatkowski, MDPhDMSc, Per Axelsson, MD, Trung Hieu Do, MD, Dorota Knut-Bojanovska, Ellen van der Spek, MDPhD, Asta Svirskaite, Pino Poddighe, MDPhD, Marian Stevens-Kroef, MD, Markus Hansson, MD PhD, Niels WCJ van de Donk, MD PhD, Einar Haukas, MD, Pieter Sonneveld, MDPhD, Niels Abildgaard, MDPhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 800.
https://doi.org/10.1182/blood-2018-99-111650
Published: 2018